Objective: Serotoninergic neurotransmission may modulate b-amyloid peptide (Ab) metabolism through upregulation of a-secretase. Early Parkinson disease (PD) shows variable serotoninergic denervation, which may impact Ab deposition. Methods: We conducted 3 analyses to explore associations between serotoninergic neurotransmission and cerebral Ab burden in PD. The first was a cross-sectional imaging study of PD subjects (n 5 23) using the serotoninergic transporter positron emission tomography (PET) ligand in Parkinson disease (PD) and synucleinopathy-associated dementias. Ab plaque deposition, assessed by amyloid positron emission tomography (PET), is associated with prevalent cognitive impairment in parkinsonian conditions. 5 Reduced cerebrospinal fluid (CSF) Ab-42 oligomers and factors influencing their metabolism are also consistently reported as risk factors for subsequent cognitive decline in PD without dementia. 6-8 Developing strategies to alter the natural history of Ab burden in PD may represent an untapped disease-modifying approach and is an emerging research priority. Variable loss of serotoninergic nerve terminals in the forebrain, striatum, and brainstem is described in PD.
C]PiB). The second was a baseline study of Parkinson's Progression Markers Initiative (PPMI) subjects exploring the influence of serotoninergic medications on cerebrospinal fluid (CSF) Ab-42 levels (n 5 389), controlling for age, sex, Geriatric Depression Scale, disease duration, and education. Third, we fit an interval censored proportional hazard model with longitudinal PPMI data (n 5 367) to test whether serotoninergic medication use associates with reduced risk of PD cognitive decline, defined as time to reach a Mon- P rogressive cerebral b-amyloid peptide (Ab) plaque burden is linked to clinically meaningful outcomesincluding cognitive decline 1,2 and gait impairments 3, 4 in Parkinson disease (PD) and synucleinopathy-associated dementias. Ab plaque deposition, assessed by amyloid positron emission tomography (PET), is associated with prevalent cognitive impairment in parkinsonian conditions. 5 Reduced cerebrospinal fluid (CSF) Ab-42 oligomers and factors influencing their metabolism are also consistently reported as risk factors for subsequent cognitive decline in PD without dementia. [6] [7] [8] Developing strategies to alter the natural history of Ab burden in PD may represent an untapped disease-modifying approach and is an emerging research priority. Variable loss of serotoninergic nerve terminals in the forebrain, striatum, and brainstem is described in PD. 9, 10 Significant loss of serotoninergic terminals is an early feature in a substantial fraction of PD subjects. 7, 8 Preclinical experiments in Alzheimer disease (AD) mouse models by Cirrito et al showed that chronic exposure to either serotonin itself or the selective serotonin reuptake inhibitor (SSRI) citalopram reduced extracellular cerebral Ab peptide concentrations and plaque burden in shortand long-term in vivo studies. 11, 12 Serotonin and SSRIs are suggested to stimulate a serotonin G-protein-coupled receptor-linked intracellular cascade that favors the cleavage of amyloid precursor protein (APP) by a-secretase, leading to reductions in toxic Ab peptide amyloid generation and reduced plaque formation. 11 Serotonin medications may also promote efflux of toxic Ab peptide species from the brain into the blood. 13 Other preclinical research supports the concept that serotoninergic neurotransmission can favorably modulate APP processing. [14] [15] [16] [17] If the same protective association between serotonin receptor activation and reduced amyloid burden exists in humans, a disease state such as PD with reductions in serotoninergic tone offers a potential model for testing this hypothesis. In a small cohort, we previously reported that regional density of cortical and striatal serotoninergic terminals in PD, measured by in vivo PET, showed inverse correlations with Ab plaque burden. 18 We present 3 analyses exploring associations between serotoninergic neurotransmission and Ab burden in PD, using different experimental designs to address 3 related hypotheses. First, using an identical multimodal imaging approach to our earlier study in a new cohort, we sought to replicate our findings that decreased cortical serotoninergic innervation is inversely associated with the severity of cortical Ab plaque burden in PD. Second, using baseline data from the multicenter Parkinson's Progression Markers Initiative (PPMI), we explored associations between serotonin medication use and CSF Ab-42 levels. Third, we conducted a longitudinal analysis of PPMI data to test whether baseline serotoninergic medication use associates with a protective effect on cognitive decline in PD, independent of existing heterogeneity in caudate dopamine transporter binding or baseline cerebral amyloid burden.
Patients and Methods

Study 1: Cross-Sectional Prospective PET Imaging Study
In a previous PD cohort (n 5 13), we reported inverse associations between cortical and striatal serotoninergic terminal and amyloid PET findings. 18 To determine whether these findings were due to cohort-specific effects, we conducted a separate cross-sectional multimodal PET imaging study of 23 PD subjects. 13, 2017 . PPMI subjects underwent screening evaluations (month 0), followed by baseline evaluations (typically at month 1), visit 1 evaluations (month 4), and subsequent evaluations on a scheduled basis-initially at 3-month intervals and then at 6-month intervals after visit 4 (month 13)-through a possible visit 12 (month 61). All subjects signed informed consent upon enrollment into the PPMI. This project, using publicly available coded PPMI data, was granted not-regulated status by the the University of Michigan IRBMED. Analyses were conducted in Stata 15 (StataCorp, College Station, TX) and SAS 9.4 (SAS Institute, Cary, NC).
Eligible subjects for our baseline analyses were those who were coded as having a primary study diagnosis of "idiopathic PD" at the time of screening visit, who had a screening visit DaT scan evaluation, who had CSF Ab-42 tested at the baseline visit, documentation of serotonin medication use at the time, and who did not accrue an alternative primary study diagnosis at a subsequent study visit. Figure 1 provides an overview of our PPMI study cohorts. We categorized serotoninergic medications to include SSRIs, 21 serotonin-norepinephrine reuptake inhibitors (SNRIs), 22 tricyclic antidepressants (TCAs), 17 bupropion, 23 lithium, 24 and St John's wort, 25 given that each of these compounds has been shown to influence serotoninergic neurotransmission. In this cross-sectional baseline study aimed at understanding the influence of serotonin medications on CSF Ab-42, we categorized subjects as those taking serotonin medications for 6 months (n 5 45) versus others (n 5 344). Serotonin medication use was treated as a categorical variable (yes/ no) and was not adjusted for dosing or weight. Age was defined as the difference between year of birth and year of study enrollment, and disease duration was defined at the number of years between when symptoms were first noticed by the subject and year of study enrollment. CSF Ab-42 levels 26 were measured at the baseline visit. Baseline CSF Ab-42 was treated as the outcome variable of interest in a multivariate linear regression using baseline cross-sectional PPMI data. Covariates included serotonin medication use, age, sex, disease duration, self-reported years of education, and baseline Geriatric Depression Scale (GDS) score on the 15-item GDS. We aimed to control for the degree of depressive symptoms using the GDS because late-life depression is known to associate both with dementia risk and with CSF Ab-42 burden. 27, 28 We controlled for years of education to account for the possibility that subjects receiving prescription serotonin medications might have unmeasured differences in socioeconomic status relative to those not on serotonin medications.
Study 2b: Longitudinal PPMI Proportional Hazard Analysis
We conducted a survival analysis in the PPMI cohort to explore the effects of serotoninergic medications on cognitive decline in PD. PD subjects who had 2 Montreal Cognitive Assessment (MoCA) scores recorded over the duration of the study, who underwent DaT SPECT at screening, and who had a screening MoCA score of >20 at study entry were eligible for inclusion (see Fig 1) . We chose progression to MoCA scores of 20 as our endpoint, given that this transition value (21!20) has been previously validated against full neuropsychological testing in PD as an optimal diagnostic cutoff point (as opposed to a "screening" cutoff value) for meeting neuropsychological criteria of impairment in at least 2 cognitive domains suggestive of dementia. 29 We aimed to define our MoCA endpoint as maninone of our longitudinal PPMI subjects were on dopaminergic PD medications at study enrollment. We first tested the unadjusted bivariate associations between several different potential explanatory variables including the use of serotoninergic medications at the time of baseline evaluation (Supplementary Table) in separate Cox proportional hazard analyses. Next, we tested associations in a multivariate model after adjusting for several baseline confounders. The nigrostriatal dopaminergic system is known to play a role in PD cognitive impairment, specifically dopamine terminal loss in the caudate nucleus. 31, 32 We estimated this using mean bilateral caudate nucleus DaT SPECT measurements from the PPMI. 33 We sought to control for heterogeneity in baseline amyloid status by using baseline CSF Ab-42 levels as a covariate as well. Covariates were tested to explore the assumption of proportional hazards. To test whether a serotonin-medication effect on MoCA decline might vary across drug classes of differing specificity for serotonin-receptor modulation, we conducted 2 separate sensitivity analyses where the serotonin medication use categorical variable was restricted to either only those subjects taking SSRIs or those subjects taking either SSRIs or TCAs.
Results
Demographic characteristics for the Study 1 cohort are presented in nonsignificant associative trend for duration of disease (t 5 3.32, p 5 0.0836). There were no significant interactions between cortical DASB DVR and disease duration.
In Study 2a, subjects on serotonin medications for at least 6 months at baseline (n 5 45) did not differ significantly in CSF Ab-42 levels from subjects not receiving serotonin medications in unadjusted analyses (mean 6 standard error [SE]: 348.5 6 15.0pg/ml vs 374.5 6 5.5pg/ml; t 5 1.62, p 5 0.11). After adjusting for confounders, the multivariate linear regression analyses (n 5 389; Table 2) showed that male sex and use of serotonin medications for at least 6 months both associated with lower levels of CSF Ab-42 at baseline. Age, disease duration, years of education, and GDS score did not show significant associations.
A total of 367 subjects met inclusion criteria for the survival analysis (Study 2b) predicting time to a decline in MoCA score of 20. Of these 367 subjects, 70 (19.1%) were using serotoninergic medications at the time of their baseline visit. Twenty-eight of the total 367 subjects progressed to develop an MoCA score of 20 as assessed at a subsequent study visit. In a bivariate Cox proportional hazard analysis, taking a serotoninergic medication at baseline did not show a significant association with decline to an MoCA of 20 (see Supplementary Table) . Table 3 34 PET studies suggest that regional serotonin terminal loss is an early event in PD. 10, 36 This early and heterogeneous loss of serotoninergic terminals may suggest a possible causal role for serotoninergic modulation of Ab peptide generation in PD, the latter of which is a later stage disease feature that also shows substantial heterogeneity in cortical plaque burden. 5 In contrast to our initial findings, we did not find a significant correlation between striatal DASB and PiB DVRs in the current cohort. This may reflect stage-specific associations not seen in our cohort, given that striatal amyloid burden has been described more commonly in PD with advanced cognitive impairment as opposed to early PD. 37, 38 Within the range of values seen in our Study 1 cohort, however, disease duration did not appear to influence the association between cortical DASB and PiB DVRs. Understanding temporal associations between early regional serotonin terminal loss and progressive amyloid plaque deposition leading to local neuronal dysfunction may be a fruitful goal for future PD natural history studies. Our Study 2a analysis results indicating lower CSF Ab-42 levels in PD subjects taking serotoninergic medications are consistent with recent preclinical and clinical data suggesting that increasing serotoninergic neurotransmission reduces Ab peptide generation. Cirrito et al demonstrated that chronic oral administration of citalopram relative to placebo in an AD mouse model diminished extracellular Ab peptide levels and led to a 62% reduction in relative cortical amyloid plaque burden after 4 months. 11 In a retrospective analysis of 177 healthy controls, the duration of serotonin medication exposure correlated with reduced cortical amyloid PET binding. 11 A separate prospective randomized trial of young healthy adults showed that those receiving an acute 60mg dose of citalopram rather than placebo experienced a 38% reduction over about 2 days in CSF Ab peptide concentrations, and the kinetics of this reduction was consistent with reduced Ab peptide generation. 12 Although higher Ab-42 CSF levels are typically associated with better cognitive outcomes in PD, interpretation of Ab-42 CSF level data is not straightforward. CSF Ab-42 CSF levels likely reflect complex interactions between Ab-42 peptide generation, clearance, and possibly sequestration in amyloid plaques. Some evidence suggests that reduced Ab-42 levels would be consistent with reduced risk of dementia. In vitro data indicate that the protective APP A673T mutation is associated with reduced Ab-42 generation. 39 Recent evidence from APP A673T mutation carriers shows reduced serum levels of Ab-42, which is expected to correlate with CSF Ab-42 levels. 40 Similarly, increased Ab-42 generation is predicted to increase dementia risk. Statistical modeling of CSF Ab-42 data from autosomal dominant AD (ADAD) mutant allele carriers followed in the Dominantly Inherited Alzheimer Network study suggests early elevation of CSF Ab-42 levels followed by decline around the estimated onset of manifest disease. 41 In this model, declining CSF Ab-42 levels in ADAD subjects is secondary to neurodegeneration causing diminished Ab-42 peptide generation and/or Ab-42 peptide sequestration in amyloid plaques. The implication is that the association between lower CSF Ab-42 levels and dementia risk is a consequence of more advanced pathology. Our finding (Study 2b) that baseline serotoninergic medication exposure reduced risk of progression to MoCA < 20 is also consistent with a beneficial modulatory effect of serotoninergic agents on Ab-42 peptide generation. Similar results were reported recently in a retrospective analysis of conversion from mild cognitive impairment to dementia in the Alzheimer Disease Neuroimaging cohort. 42 Antidepressant medications were also suggested to reduce dementia incidence in analyses from Kessing et al in datasets drawn from large Danish registries of prescription drugs. 43, 44 Our sensitivity analyses did not show significant associations of SSRIs and SSRIs/ TCAs with time to MoCA decline. Given the relatively similar hazard ratios but increased hazard ratio SEs for the serotonin medication use variable in these subgroup analyses, these findings may be a manifestation of an expected reduction in statistical power with fewer subjects subsequently identified as having the exposure of interest. 45 Alternatively, they may reflect either the possibility that nonserotonin neuronal systems are preferentially involved in altering the risk of PD cognitive decline or the possibility that only a low degree of serotonin receptor modulation may be needed to yield a protective cognitive effect. Serotoninergic medications are used early and often in PD to treat symptoms of depression, anxiety, sleep disorders, or other nonmotor features. In the PPMI cohort, about 20% of subjects were on serotoninergic medications at baseline. A community-based PD registry study in Sweden estimated the rate to be 22% in homedwelling individuals and 50% in those residing in an institution. 46 To date, PD trials that have studied the efficacy of SSRIs, SNRIs, or TCAs typically employed relatively short study assessment periods (weeks to months) focused on symptomatic modification of selfreported affective symptoms and have not measured cerebral amyloid burden. 47, 48 One post hoc analysis of a 4-month randomized PD antidepressant trial showed no clear benefit of paroxetine or nortriptyline on cognitive performance relative to placebo but was limited to a small sample size and short follow-up duration. 49 The possible beneficial effect of certain TCAs on amyloidlinked cognitive decline may also be confounded by their anticholinergic properties. A systematic review by Moraros et al investigated the association between antidepressant drugs and dementia risk and found a higher unadjusted dementia risk in subjects initiated on antidepressants before age 65 years. 50 These findings are likely to be influenced by the severity and variable causes of comorbid depression. They do, however, raise the possibility that there may exist a critical time window for serotoninergic neurodegeneration-induced acceleration of cerebral amyloid burden. This may be relevant for the design of future interventional studies. Our Study 2b clinical findings would benefit from validation not only in other PD cohorts but also in prospective longitudinal studies of aging that could control for drug class and dosing. Limitations of our study include the possibility of differential censoring. Only a small fraction of eligible subjects progressed to an MoCA score of 20, raising the possibility that some subjects with declining cognition might have been lost to follow-up and would thereby not be captured in this dataset. It is possible that such censoring occurred and may influence these data.
Subjects enrolled in the PPMI may represent a skewed population, given that their parkinsonian symptoms were not severe enough to require the use of dopaminergic medications at the time of enrollment. This cohort factor may limit the generalizability of our findings. Because of power concerns, we were not able to control for a greater number of covariates, given the limited number of subjects who did progress to the MoCA endpoint. Some PPMI subjects showed variability in MoCA scoring from one visit to the next. We chose our endpoint specifically for the purpose of accurately identifying newly developed probable dementia rather than as a screening cutoff for subjects at risk for dementia. This effort to more precisely define a cognitive state transition point limited the number of PPMI subjects who met our primary endpoint. This tradeoff, however, comes with improved precision as it relates to our assessment of baseline risk factors associated with longitudinal cognitive decline. Our previously published cross-sectional DASB-PiB PD PET imaging cohort 18 had an even higher mean age (68.38 years) and lower mean MoCA (24.3) than the 23-subject imaging cohort in Study 1. In the present analyses, subjects enrolled in Study 1 were older, had longer disease duration, and had lower MoCA scores than subjects in the PPMI. This may limit how translatable findings from Study 1 are to the cohort in Study 2 and vice versa. Conversely, these findings may also collectively shed light into different aspects of the natural history of serotoninergic neurodegeneration across different disease stages in PD. We acknowledge that our findings do not directly test the protective causal mechanism that we hypothesize exists between serotoninergic medications, a-secretase activity, and the degree of cerebral amyloid burden in PD. It is possible that subjects in this cohort receiving serotoninergic medications from their personal clinicians may have other unmeasured factors that influence amyloid burden and/or cognition, including severity and subtypes of affective symptoms or factors that associate with greater access to care and prescription medications. Given the wide variety, dosing, and duration of use of serotoninergic medications by subjects, we were not able to explore a dose-response relationship.
Developing treatments for different causes of cerebral amyloid burden is a goal relevant not only to PD but to a majority of patients affected by neurodegenerative diseases. Our PD findings are strengthened by the multicenter nature of the PPMI but would benefit from replication in other representative PD datasets. Serotoninergic medications are well tolerated in PD patients, and SSRIs targeted against cerebral amyloid burden merit consideration for future PD clinical trials. Such trials might be usefully enhanced by use of serotonin terminal imaging to select or stratify the subject population.
